2 completed, 2 not yet recruiting, 2 recruiting. 2 Phase 3, 1 Not applicable, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Not yet recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Palmoplantar Pustulosis (PPP): new trials by email Literature Review of Palmoplantar Pustulosis (PPP) trials Research Report on Palmoplantar Pustulosis (PPP)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tofacitinib Plus Imatinib in Moderate-to-Severe Palmoplantar Pustulosis Tofacitinib, Imatinib, tofacitinib Placebo - Palmoplantar Pustulosis (PPP) | Phase 3 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 135 | 2026-08-01 | 2026-08-03 |
| Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis Xeligekimab Injection - Palmoplantar Pustulosis (PPP) | Phase 4 | Recruiting | First Hospital of China Medical University | 10 | 2026-03-01 | 2026-03-31 |
| A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar Pustulosis Ivarmacitinib - Palmoplantar Pustulosis (PPP) | Not applicable | Recruiting | Xijing Hospital | 60 | 2025-10-01 | 2025-12-08 |
| Construction of a Psoriasis and Psoriatic Arthritis Diagnostic Model Based on Multidimensional Nail Information No intervention - Psoriasis (PsO), Psoriatic Arthritis | Not yet recruiting | Shanghai Yueyang Integrated Medicine Hospital | 310 | 2025-01-20 | 2025-01-24 | |
| Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis Risankizumab, Placebo - Palmoplantar Pustulosis (PPP) | Phase 3 | Completed | AbbVie | 119 | 2020-07-20 | 2022-12-05 |
| A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis Spesolimab, Placebo - Palmoplantar Pustulosis (PPP) | Phase 2 | Completed | Boehringer Ingelheim | 152 | 2019-07-31 | 2025-10-16 |
Psoriasis (6) · Arthritis, Psoriatic (1)
Skin Diseases (6) · Skin Diseases, Papulosquamous (6) · Skin and Connective Tissue Diseases (6) · Arthritis (1) · Bone Diseases (1) · Joint Diseases (1) · Musculoskeletal Diseases (1) · Spinal Diseases (1) · Spondylarthritis (1) · Spondylarthropathies (1) · Spondylitis (1)
Imatinib Mesylate (1) · ivarmacitinib (1) · risankizumab (1) · spesolimab (1) · tofacitinib (1)
AbbVie (1) · Boehringer Ingelheim (1) · First Hospital of China Medical University (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Shanghai Yueyang Integrated Medicine Hospital (1) · Xijing Hospital (1)
China (3) · Japan (2) · Australia (1) · Belgium (1) · Canada (1) · Czechia (1) · France (1) · Germany (1) · Hungary (1) · Netherlands (1) · Poland (1) · Russia (1) · South Korea (1) · Taiwan (1) · United Kingdom (1)
2018 (1)